Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Cryogenic Solutions Inc. (CYGS) -- Ignore unavailable to you. Want to Upgrade?

To: Daddy-oh who wrote (3121)	8/18/1998 11:13:00 AM
From: Graham Marshman	Read Replies (1) \| Respond to of 4028

For those interested, this is an attempt at a laymans (that's me) description of CYGS medical claim value. Comments appreciated. There are other pieces out there on antisense, I know, just wanted a fairly concise story. Graham DNA is resident in the cell nucleus in a double strand. Each strand consists of four molecule types (codons) arranged in a code sequence. Markers along the strand separate the code into individual "sentences". Essentially, each specific code sentence keys the generation of a specific protein to perform a function in the body. The process of protein generation starts with an enzyme, which senses the code pattern in a specific sentence on the main DNA strand and makes a length of messenger-RNA which copies the code. The messenger RNA then travels from the nucleus into the main body of the cell, and delivers it to a protein production facility (ribosome.) Many diseases can be linked with an incorrect production of proteins. This can be caused either by faulty DNA code or by a false code inserted by a virus. Antisense is the process of preventing the transmission of an undesirable sensed code to the protein production facility and so preventing the production of the unwanted protein. This is done by disabling messenger-RNA with the specific targeted code sequence. Messenger RNA can be disabled by introducing a single strand of antisense RNA or DNA into the cell. This strand is a mirror image of the code in the targeted messenger RNA and so will bind to it (hybridize.) Once hybridized, the RNA can no longer trigger protein production and in fact will be destroyed by normal cell processes. Current trials in the body (in vivo) have used antisense RNA. While relatively easy to deliver to the cell this has limited lifetime and limited bonding attraction to the messenger-RNA so has limited effectiveness. Laboratory testing (in vitro) using antisense DNA shows better bonding, longer life and higher effectiveness, but no means of getting the antisense DNA into living cells in the body has been identified. CYGS claims to solve this problem by offering a means of delivering single strand DNA into body cells. The delivered single strand DNA can be programmed to be any desired code so allowing it to be used with any of the existing antisense molecules. Delivery is also targeted to specific cell types - current work at CYGS is addressed at increasing the cell types supported.